carcinoembryonic antigen

(redirected from Cancer Antigens)
Also found in: Dictionary, Medical, Wikipedia.
Related to Cancer Antigens: CA125 ovarian cancer antigen

carcinoembryonic antigen

[¦kärs·ən·ō‚em·brē¦än·ik ′ant·i·jən]
(immunology)
A glycoprotein found in tissues of the fetal gut during the first two trimesters of pregnancy and in the peripheral blood of individuals with some forms of cancer, such as digestive-system or breast cancer.
References in periodicals archive ?
At a recent American Society of Clinical Oncology (ASCO) meeting, additional evidence was presented showing that the new test system using a panel of six cancer antigens (p53, NY-ES0-1, CAGE, GBU4-5, Annexin 1, and SOX2), when run on an ELISA platform, was able to detect autoantibodies, or "immuno-biomarkers," to lung cancer.
We are on track to file an Investigational New Drug (IND) application for ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells at the end of 2012.
Vile deployed the human vaccine prostate cancer antigens through the mutated VSV vector to raise a full-on assault from the mice's T-cells.
ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells and a preclinical antigen-specific T-cell therapy program.
This directly introduces the attached cancer antigens inside the immune system cells.
The candidates vaccines and antibodies identified in this report target 17 different cancer antigens or (antibody) drug targets and these developments are being taken forward by 30 different companies.
National Cancer Institute (NCI) Study Published in Science Used PGDx Exome Sequencing to Identify Epithelial Cancer Antigens with Demonstrated Immunotherapy Potential--
These candidate breast cancer vaccines and antibodies target 17 cancer antigens or antibody targets, and are being taken forward by 30 companies.
Cover Story Discusses MabCure's Hybridoma Approach to Seek Ovarian Cancer Antigens
It is this ability of PMED to produce a robust and reproducible T-cell mediated immune response to a broad range of viral and cancer antigens, that provides PowderMed with its unique competitive advantage in the field of DNA-based vaccines.
Yvonne Paterson of the University of Pennsylvania has developed a promising immunotherapeutic platform and technology that lends itself to delivering immune triggers against a number of cancer antigens.
The following RUO (Research Use Only) immunoassay kits for quantitative determination of cancer antigens are available immediately: alpha-fetoprotein (AFP); carcinoembroyonic antigen (CEA); CA125; CA15-3; CA 19-9; PSA; free PSA (f-PSA); free beta subunit of human chorionic gonadotropin (free beta-hCG) and beta-2 Microglobulin (B2MG).